These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 19907330

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Experience with bisphosphonates in osteogenesis imperfecta.
    Glorieux FH.
    Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
    [Abstract] [Full Text] [Related]

  • 3. Osteogenesis imperfecta, current and future medical treatment.
    Rauch F, Glorieux FH.
    Am J Med Genet C Semin Med Genet; 2005 Nov 15; 139C(1):31-7. PubMed ID: 16278881
    [Abstract] [Full Text] [Related]

  • 4. [Oesteogenesis imperfecta--genetics, diagnosis and medical treatment].
    Brixen KT, Illum NO, Hansen B, Lund AM, Mosekilde L.
    Ugeskr Laeger; 2007 Jan 01; 169(1):30-4. PubMed ID: 17217883
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T, Turan S, Guran T, Bereket A.
    Indian Pediatr; 2008 Feb 01; 45(2):105-9. PubMed ID: 18310788
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
    D'Eufemia P, Finocchiaro R, Zambrano A, Tetti M, Ferrucci V, Celli M.
    Biomed Pharmacother; 2007 May 01; 61(4):235-40. PubMed ID: 17275249
    [Abstract] [Full Text] [Related]

  • 18. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates.
    Malmgren B, Aström E, Söderhäll S.
    J Oral Pathol Med; 2008 Apr 01; 37(4):196-200. PubMed ID: 18321345
    [Abstract] [Full Text] [Related]

  • 19. Bisphosphonate treatment of pediatric bone disease.
    Speiser PW, Clarson CL, Eugster EA, Kemp SF, Radovick S, Rogol AD, Wilson TA, LWPES Pharmacy and Therapeutic Committee.
    Pediatr Endocrinol Rev; 2005 Dec 01; 3(2):87-96. PubMed ID: 16361982
    [Abstract] [Full Text] [Related]

  • 20. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
    Gökşen D, Coker M, Darcan S, Köse T, Kara S.
    Turk J Pediatr; 2006 Dec 01; 48(2):124-9. PubMed ID: 16848111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.